| Price | ₹540 - ₹570 |
| Premium | ₹91 |
|---|---|
| Lot size | 26 |
| Allotment | Jul 17, 2025 |
| Listing | Jul 21, 2025 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 26 | 14820 | 799840 |
| sHNI | 14 | 364 | 207480 | 8162 |
| bHNI | 68 | 1768 | 1007760 | 16323 |
IPO Details
| Total Issue Size | 59,561,404 shares (aggregating up to 3,395.00 Cr) |
| Offer For Sale | 59,561,404 shares (aggregating up to 3,395.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 55,90,77,100 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not less than 15.00% of the Net Issue |
Key Performance Indicator (KPI)
| KPI | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 20.82% | 20.04% | 24.89% |
| ROCE | 26.88% | 25.71% | 31.69% |
| RONW | 20.82% | 20.03% | 24.93% |
| EPS (basic) | 8.04 | 6.48 | 6.75 |
| P/E Pre IPO | 70.62 | ||
| P/E Post IPO | 70.62 |
Comapny Financial In Crore
| Period Ended | Mar-25 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 | 1,618.87 |
| Revenue | 1,930.28 | 1,483.07 | 1,133.99 | 1,280.24 |
| Profit After Tax | 451.25 | 367.31 | 385.19 | 405.54 |
| Net Worth | 2,409.86 | 1,924.66 | 1,740.67 | 1,355 |
| Total Borrowing | 108.95 | 232.53 | 125.06 | 35.49 |
About Company
Anthem Biosciences Limited: Company Overview
Established in 2006, Anthem Biosciences Limited is a rapidly growing Indian Contract Research, Development, and Manufacturing Organization (CRDMO). The company provides end-to-end support across the drug development journey, covering everything from early-stage discovery to full-scale commercial manufacturing.
Products and Services
Anthem Biosciences specializes in producing fermentation-derived active pharmaceutical ingredients (APIs). These include:
------> Probiotics
------> Enzymes
------> Peptides
------> Vitamin analogues
------> Biosimilars
Their integrated services span the entire lifecycle of a pharmaceutical molecule, making them a trusted partner for drug discovery, formulation, development, and market-scale production.
Global Reach and Clientele
As of September 30, 2024, the company had built a global footprint, working with 425+ clients across 44 countries. This diverse base includes top markets like the United States, Europe, and Japan. Clients range from small biotech startups to multinational pharmaceutical giants, reflecting the company’s versatile service model.
Research, Development & Intellectual Property
Anthem maintains a strong innovation pipeline, with 196 active projects in various stages—ranging from discovery to commercial execution. The company also holds a valuable IP portfolio comprising:
------> 8 granted patents (1 in India, 7 internationally)
------> 24 patent applications pending across global jurisdictions
Workforce and Expertise
By September 2024, Anthem employed a team of 600 professionals, including chemists, biologists, and engineers. This highly skilled talent pool operates across multiple scientific domains, reinforcing the company’s technical edge in the pharmaceutical sector.
Key Strengths
1. Comprehensive CRDMO Services for Both Small and Large Molecules
Anthem offers a fully integrated and customizable platform for pharmaceutical clients, covering both small molecules (NCEs) and biologics (NBEs). It is recognized as India’s fastest-growing CRDMO and is the only one with a strong position across all molecule categories, as per the F&S Report.
2. Strategic Focus on Emerging Pharma and Biotech Companies
Unlike conventional players, Anthem focuses on emerging pharmaceutical and biotech firms, helping them scale by providing regulatory expertise, advanced infrastructure, and scalable manufacturing support. This niche focus allows the company to tap into high-growth segments driven by innovation.
3. Scalable Manufacturing and World-Class Infrastructure
Anthem operates two cGMP-compliant production facilities, with a fermentation capacity of 142 kL (as of September 2024). The company is also expanding capacity to 182 kL, which is six times larger than the next-biggest Indian CRDMO. This significant scale, backed by heavy capital investment, ensures high-volume, compliant, and automated manufacturing operations.
Identified Weaknesses
1. Risk from Regulatory Inspections and Compliance Challenges
Anthem’s production units are routinely inspected by global regulatory bodies such as the USFDA and PMDA Japan. Any delays or issues in meeting compliance standards—particularly in ESG and evolving quality frameworks—can negatively impact manufacturing timelines and revenues.
2. Dependence on Limited Manufacturing Units
The company is heavily reliant on its Unit I, Unit II, and the under-construction Unit III. Any operational disruption—such as technical failures, labor shortages, or raw material constraints—can result in project delays, cost overruns, and revenue losses, impacting both the CRDMO and specialty ingredients divisions.
3. Exposure to Industrial Hazards
Anthem's research and manufacturing involve flammable and hazardous materials, increasing the risk of accidents or fires. Despite upgrading safety protocols following a fatal incident in 2018, the company remains exposed to potential industrial hazards or natural disasters. Such events could lead to operational shutdowns, increased costs, and human or material damage.
![Mitchell Marsh Net Worth [2025 Update]: Career Earnings, Income Sources, and Lifestyle](https://blogger.googleusercontent.com/img/a/AVvXsEiD9IxbReBx4M1nONyUWX_pXRO-yieC_vr6locGR2s-94hEpblyueTtNUvaYQ__KVQ3yOtfwgZK2v4OmtZ-L4QNRZSs3adAWfV-s06jRXvgSiCpewuyncTVoE110RRX3LTuWoimZ07JzyDy0uzvBxllhJPaWtJBFf6fRwkhO_d0oHCRjOdCRZNSBNQcqZo=w72-h72-p-k-no-nu)
0 Comments